MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network

Giovanni Battista Migliori; Simon Tiberi; Alimuddin Zumla; Eskild Petersen; Jeremiah Muhwa Chakaya; Christian Wejse; Marcela Muñoz Torrico; Raquel Duarte; Jan Willem Alffenaar; H Simon Schaaf; Ben J Marais; Daniela Maria Cirillo; Riccardo Alagna; Adrian Rendon; Emanuele Pontali; Alberto Piubello; José Figueroa; Gabriella Ferlazzo; Alberto García-Basteiro; Rosella Centis; Dina Visca; Lia D'Ambrosio; Giovanni Sotgiu; members of the Global Tuberculosis Network

doi:10.1016/j.ijid.2020.01.042

MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network

Int J Infect Dis. 2020 Mar:92S:S15-S25. doi: 10.1016/j.ijid.2020.01.042. Epub 2020 Feb 4.

Authors

Giovanni Battista Migliori¹, Simon Tiberi², Alimuddin Zumla³, Eskild Petersen⁴, Jeremiah Muhwa Chakaya⁵, Christian Wejse⁶, Marcela Muñoz Torrico⁷, Raquel Duarte⁸, Jan Willem Alffenaar⁹, H Simon Schaaf¹⁰, Ben J Marais¹¹, Daniela Maria Cirillo¹², Riccardo Alagna¹³, Adrian Rendon¹⁴, Emanuele Pontali¹⁵, Alberto Piubello¹⁶, José Figueroa¹⁷, Gabriella Ferlazzo¹⁸, Alberto García-Basteiro¹⁹, Rosella Centis²⁰, Dina Visca²¹, Lia D'Ambrosio²², Giovanni Sotgiu²³; members of the Global Tuberculosis Network

Collaborators

members of the Global Tuberculosis Network:
T Abu Arkub²⁴, O W Akkerman²⁵, A Aleksa²⁶, E Belilovski²⁴, E Bernal²⁷, F-X Blanc²⁸, M Boeree²⁵, S Borisov²⁴, J Bruchfeld²⁹, J Cadiñanos Loidi²⁷, J A Caminero²⁷, A C Carvalho³⁰, J J Cebrian Gallardo²⁷, Charalampos³¹, E Danila³², L Davies Forsman²⁹, J Denholm, K Dheda³³, R Diel³⁴, S Diktanas³², C Dobler³⁵, M Enwerem³³, S Esposito³⁶, N Escobar Salinas³⁷, A Filippov²⁴, B Formenti³⁶, J M García García²⁷, D Goletti³⁶, R Gomez Rosso³⁸, G Gualano³⁶, P Isaakidis³³, A Kaluzhenina²⁴, S Koirala³⁹, L Kuksa⁴⁰, H Kunst⁴¹, Y Li⁴², C Magis-Escurra²⁵, V Manfrin³⁶, S Manga⁴³, K Manika³¹, V Marchese³⁶, E Martínez Robles²⁷, A Maryandyshev²⁴, A Matteelli³⁶, A Mariani³⁰, J Mazza-Stalder⁴⁴, F Mello³⁰, L Mendoza³⁷, A Mesi⁴⁵, S Miliauskas³², H Mustafa Hamdan⁴⁶, N Ndjeka³³, M Nieto Marcos²⁷, T H M Ottenhoff²⁵, D J Palmero⁴⁷, F Palmieri³⁶, A Papavasileiou³¹, M C Payen⁴⁸, A Pontarelli³⁶, M Pretti Dalcolmo³⁰, S Quirós Fernandez²⁷, R Romero³³, D Rossato Silva³⁰, A P Santos³⁰, B Seaworth⁴⁹, M Sinitsyn²⁴, A Skrahina²⁶, I Solovic⁵⁰, A Spanevello³⁶, M Tadolini³⁶, C Torres⁵¹, Z Udwadia⁵², M van den Boom⁵³, G V Volchenkov²⁴, A Yedilbayev⁵³, R Zaleskis⁴⁰, J P Zellweger⁴⁴

Affiliations

¹ Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy. Electronic address: [email protected].
² Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom. Electronic address: [email protected].
³ Division of Infection and Immunity, University College London and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: [email protected].
⁴ Directorate General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman; Institute for Clinical Medicine, Faculty of Health Science, University of Aarhus, Denmark; ESCMID Emerging Infections Task Force, Basel, Switzerland. Electronic address: [email protected].
⁵ The International Union Against Tuberculosis and Lung Disease, Paris, France; Department of Medicine, Therapeutics, Dermatology and Psychiatry, Kenyatta University, Nairobi, Kenya. Electronic address: [email protected].
⁶ Department of Infectious Disease, Aarhus University Hospital and School of Public Health, Faculty of Health Sciences, University of Aarhus, Denmark. Electronic address: [email protected].
⁷ Clínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico. Electronic address: [email protected].
⁸ National Reference Centre for MDR-TB, Hospital Centre Vila Nova de Gaia, Department of Pneumology, Public Health Science and Medical Education Department, Faculty of Medicine, University of Porto, Porto, Portugal. Electronic address: [email protected].
⁹ Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Westmead Hospital, Sydney, Australia; Dept. Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands. Electronic address: [email protected].
¹⁰ Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa. Electronic address: [email protected].
¹¹ The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia; The University of Sydney Marie Bashir Institute for Infectious Diseases and Biosecurity, Sydney, New South Wales, Australia. Electronic address: [email protected].
¹² Emerging Pathogens Unit, TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milan, Italy. Electronic address: [email protected].
¹³ Emerging Pathogens Unit, TB Supranational Reference Laboratory, San Raffaele Scientific Institute, Milan, Italy. Electronic address: [email protected].
¹⁴ Centro de Investigación, Prevención y Tratamiento de Infecciones Respiratorias CIPTIR, University Hospital of Monterrey UANL (Universidad Autonoma de Nuevo Leon), Monterrey, Mexico. Electronic address: [email protected].
¹⁵ Department of Infectious Diseases, Galliera Hospital, Genova, Italy. Electronic address: [email protected].
¹⁶ The International Union Against Tuberculosis and Lung Disease, Paris, France; Tuberculosis Division, Damien Foundation, Niamey, Niger. Electronic address: [email protected].
¹⁷ National Health Service (NHS) England, London, United Kingdom. Electronic address: [email protected].
¹⁸ Southern Africa Medical Unit, Médecins Sans Frontières, Cape Town, South Africa. Electronic address: [email protected].
¹⁹ Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique; ISGlobal, Barcelona Centre for International Health Research, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain. Electronic address: [email protected].
²⁰ Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Via Roncaccio 16, Tradate, Varese, 21049, Italy. Electronic address: [email protected].
²¹ Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy; Department of Medicine and Surgery, Respiratory Diseases, University of Insubria, Varese, Italy. Electronic address: [email protected].
²² Public Health Consulting Group, Lugano, Switzerland. Electronic address: [email protected].
²³ Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. Electronic address: [email protected].
²⁴ Russian Federation.
²⁵ Netherlands.
²⁶ Belarus.
²⁷ Spain.
²⁸ France.
²⁹ Sweden.
³⁰ Brazil.
³¹ Greece.
³² Lithuania.
³³ South Africa.
³⁴ Germany.
³⁵ Australia.
³⁶ Italy.
³⁷ Chile.
³⁸ Paraguay.
³⁹ Nepal.
⁴⁰ Latvia.
⁴¹ UK.
⁴² China.
⁴³ Peru.
⁴⁴ Switzerland.
⁴⁵ Albania.
⁴⁶ Sudan.
⁴⁷ Argentina.
⁴⁸ Belgium.
⁴⁹ USA.
⁵⁰ Slovakia.
⁵¹ Colombia.
⁵² India.
⁵³ Denmark.

PMID: 32032752
DOI: 10.1016/j.ijid.2020.01.042

Abstract

The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Global Tuberculosis Network (GTN) experts. The core published documents and guidelines have been reviewed, including the recently published MDR-TB WHO rapid advice and ATS/CDC/ERS/IDSA guidelines. After a rapid review of epidemiology and risk factors, the clinical priorities on MDR-TB diagnosis (including whole genome sequencing and drug-susceptibility testing interpretations) and treatment (treatment design and management, TB in children) are discussed. Furthermore, the review comprehensively describes the latest information on contact tracing and LTBI management in MDR-TB contacts, while providing guidance on post-treatment functional evaluation and rehabilitation of TB sequelae, infection control and other public health priorities.

Keywords: Diagnosis; MDR-TB; Prevention; Rehabilitation of sequelae; Treatment; XDR-TB.

Publication types

Review

MeSH terms

Adult
Child
Child, Preschool
Contact Tracing
Extensively Drug-Resistant Tuberculosis / diagnosis*
Extensively Drug-Resistant Tuberculosis / drug therapy*
Humans
Infection Control
Latent Tuberculosis / drug therapy
Practice Guidelines as Topic
Risk Factors
Tuberculosis, Multidrug-Resistant / diagnosis*
Tuberculosis, Multidrug-Resistant / drug therapy*
Tuberculosis, Multidrug-Resistant / epidemiology
Tuberculosis, Multidrug-Resistant / prevention & control